BioSpace News Archive

Lyra Therapeutics, Inc. announced that it has issued an equity-based award pursuant to its 2022 Inducement Award Plan to its Senior Vice President of Quality, Gloria Cosgrove, upon the commencement of her employment.

IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today announced the completion of nearly US $75 million ($500 million RMB) in Series C1 funding.

Shanghai Junshi Biosciences Co., Ltd announced that the new drug application for Deuremidevir Hydrobromide Tablets, an oral nucleoside analog anti-SARS-CoV-2 drug, has been accepted by the National Medical Products Administration for the treatment of the coronavirus disease 2019.

Shanghai Junshi Biosciences Co., Ltd announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study of the company’s anti-PD-1 monoclonal antibody, toripalimab, in combination with platinum-containing doublet chemotherapy as perioperative treatment for operable non-small cell lung cancer patients, has finished the pre-specified interim analysis.